This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Japan IP Court cancels Chugai antibody patents, citing routine Fc mutation as obvious

By Toko Sekiguchi ( October 28, 2025, 08:01 GMT | Insight) -- Japan’s Intellectual Property High Court invalidated two patents held by Chugai Pharmaceutical for bispecific antibody technology, finding that the claimed Fc-region amino acid substitutions were obvious to skilled researchers and could not sustain patent protection for technology used in Genmab’s antibody platform.Japan’s Intellectual Property High Court invalidated two patents held by Chugai Pharmaceutical for bispecific antibody technology, finding that the claimed Fc-region amino acid substitutions were obvious to skilled researchers and could not sustain patent protection for technology used in Genmab’s antibody platform....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections